Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | HPGD | P15428 | 4/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 6/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | APEX1 | P27695 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.54 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28117698 | 0.99 | KDM4E (0.67) | KDM4EHPGDHSD17B10ALDH1A1TSHR | |
| SCHEMBL12485507 | 0.90 | KDM4E (0.54) | KDM4EHPGDHSD17B10ALDH1A1TSHR | |
| SCHEMBL30906937 | 0.89 | KDM4E (0.57) | KDM4EHPGDHSD17B10ALDH1A1TSHR | |
| SCHEMBL5544803 | 0.89 | KDM4E (0.57) | KDM4EHPGDHSD17B10ALDH1A1TSHR | |
| SCHEMBL3979676 | 0.84 | KDM4E (0.70) | KDM4EHPGDHSD17B10ALDH1A1TSHR | |
| SCHEMBL7057692 | 0.84 | KDM4E (0.70) | KDM4EHPGDHSD17B10ALDH1A1TSHR | |
| SCHEMBL5544822 | 0.84 | LMNA (0.73) | ALDH1A1LMNA | |
| SCHEMBL9027382 | 0.83 | KDM4E (0.68) | KDM4EHPGDHSD17B10ALDH1A1TSHR | |
| SCHEMBL30390219 | 0.83 | KDM4E (0.68) | KDM4EHPGDHSD17B10ALDH1A1TSHR | |
| SCHEMBL11948562 | 0.83 | KDM4E (0.68) | KDM4EHPGDHSD17B10ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104292159-B | A kind of preparation method of norfloxacin, ciprofloxacin and enrofloxacin | 浙江同丰医药化工有限公司 | 2016-12-07 | — | — | CN | disclosed |
| US-8889706-B2 | Soluble mTOR complexes and modulators thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-11-18 | — | — | US | disclosed |
| EP-2350053-B1 | Modulators of MTOR Complexes | WHITEHEAD BIOMEDICAL INST (US) | 2013-12-11 | — | — | EP | disclosed |
| CN-103420938-A | Method for recovering piperazine after piperazine condensation reaction in quinolone medicine preparation | ZHEJIANG JINGXIN PHARMACEUTICAL CO LTD | 2013-12-04 | — | — | CN | disclosed |
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8394818-B2 | Soluble mTOR complexes and modulators thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2011-11-24 | — | — | US | disclosed |
| US-7323596-B2 | Antibacterial or antiprotozoal activity: formula (1) formula (2) wherein: Z represents a radical of formula N(OH)CH( .dbd. O) or of formula C( .dbd. O)NH(OH); R1 represents hydrogen, methyl or trifluoromethyl, or, except when Z is a radical of | DE NOVO PHARMACEUTICALS LTD. (GB) | 2008-01-29 | — | — | US | disclosed |
| US-20040102491-A1 | Antimicrobial agents | DE NOVO PHARMACEUTICALS LTD. (GB) | 2004-05-27 | — | — | US | disclosed |
| EP-1343753-A2 | ANTIMICROBIAL AGENTS | De Novo Pharmaceuticals Ltd. (GB) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002050081-A2 | ANTIMICROBIAL AGENTS | DE NOVO PHARMACEUTICALS LTD (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | MTOR, RICTOR, RPTOR | KDM4E 2853/4885HPGD 3777/4885HSD17B10 3334/4885 |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | MTOR, RICTOR, RPTOR | KDM4E 2853/4885HPGD 3777/4885HSD17B10 3334/4885 |
| US-20040102491-A1 | Antimicrobial agents | CBR1, CYC1, MRM1 | KDM4E 2673/4885HPGD 2093/4885HSD17B10 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.